6:04 PM
Dec 14, 2012
 |  BC Extra  |  Company News

Kynamro gets thumbs down from CHMP

EMA's CHMP issued a number of negative opinions on Friday, including a recommendation against approval of an MAA for Kynamro mipomersen from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat homozygous familial hypercholesterolemia (hoFH). The committee said that while Kynamro was effective at reducing LDL-C, the product's...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >